Skip to Main Content

Paper Details

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.
JCO Precis Oncol
20
2018
EGFR, EGFR mutation-positive lung cancers, Epidermal Growth Factor Receptor, Lung Cancer, T790M, T790M and T790 Wild-Type Resistant Subclones, anti-EGFR, epidermal growth factor receptor, nazartinib, patients, tumor, tumor subclones
Author NameAffiliation
Anthony J IafrateMassachusetts General Hospital
Dora Dias-SantagataMassachusetts General Hospital
Ignaty LeshchinerEli and Edythe L. Broad Institute of MIT and Harvard.
Subba R DigumarthyMassachusetts General Hospital
Rebecca Nagy
Lecia V SequistMassachusetts General Hospital
  • 1 - 6

Datasets

Release 1.2